NASH: The silent killer that has everyone talking
NASH is a silent chronic disease that remains asymptomatic until the complications of liver cirrhosis are manifested. Patients are often only diagnosed when they develop signs of advanced liver disease, which makes it all the more dangerous.
The problem that’s only getting worse.
Certain risk factors, such as diabetes, hypertension, obesity, and known fatty liver disease, identify those patients who should undergo additional NASH screening and evaluation. However, liver enzyme blood testing is normal in as many as 80% of patients. This is why additional technologies provided by ObjectiveGI are needed for accurate diagnoses.
Between 80 and 100 million Americans have nonalcoholic fatty liver disease (NAFLD). Tens of millions of people of all ages and from all walks of life suffer from NASH. This is defined when the fat deposits in the liver cause inflammation. In a large percentage of those affected, scarring can develop in the liver, and this is known as fibrosis. Many will develop the advanced form of NASH, which eventually leads to cirrhosis and other complications.
By 2021, NASH will be the number one indication for liver transplantation. In addition to liver failure, NASH patients also face a dramatically increased risk for liver cancer. The NASH epidemic is already causing a huge economic strain, and it’s only getting worse. Today, we’re spending $5 billion annually in healthcare costs related to the disease. By 2030, this could rise to $30 billion.
A look at the NASH numbers.
The number of people in the US who have NASH
The amount the US spends annually in healthcare costs related to NASH
The global market for new NASH drugs
When NASH will be the leading indication for liver transplant in the US
Targeting the NASH global prevalence.
Because NASH is a growing epidemic with no approved therapies, our recourse is clear: increased awareness of this disease, aggressive screening, and focused gastrointestinal research in NASH. Evaluating new medicines in patients burdened by this condition is our way forward. Clinical trials have always led the way in the development of new treatments and therapies, and they’re absolutely vital here. It’s our aim at ObjectiveGI to facilitate these trials by partnering with top GI physicians caring for an abundance of afflicted NASH patients and with pharmaceutical sponsors who are dedicated to bringing promising scientific breakthroughs to the clinic. Our methods and technologies are transforming the care of patients with NASH.
Easing the burden.
While there currently are no treatments, our NASH research platform creates more regular, face-to-face patient care and monitoring. This increases patient engagement, identifies disease progression early, and improves health outcomes. This is what we provide at ObjectiveGI.
We promote lifestyle and diet changes that can have an immediate positive impact once a patient is diagnosed. Through our research partnerships, we are playing a major role in discovering the first available treatments for those eagerly anticipating discovery.
For patients in search of supplemental information and support regarding NASH, the following leading advocacy groups are available.